• Worries about CDC pathogen handling

    In a new $214 million infectious disease laboratory at the Center for Disease Control and Prevention in Atlanta, scientists are conducting experiments on bioterror bacteria in a room with a containment door sealed with duct tape

  • Environmental report on new Biolab

    Following a GAO report which criticized how DHS decided on how research into contagious foreign animal and zoonotic diseases should be conducted, the Science and Technology Directorate of DHS issues a draft environmental impact statement and risk analysis for the six locations being considered for the new Biolab

  • Investing in biodefense companies, II

    Billions of dollars are being spent on finding vaccines and treatments for possible bioterror attacks; investment analyst says that these billions of dollars in government spending notwithstanding, when considering an investment in a company doing R&D in the bioterror field, you should consider its non-terror-related biotechnology efforts, and the quality of its management team

  • Good results in tests for BioNeutral's anti-anthrax technology

    New Jersey company uses its Ygiene formulation to kill anthrax spores on contact; formulation killed all anthrax spores exposed to the formulation in as little fifteen seconds

  • Universal biosensor would detect disease, bioterror attack, pollution

    A consortium of U.K. research institutions, in collaboration with a Chinese University, work on developing a universal biosensor which would help in many types of detection — from home diagnosis of disease to chemical plant monitoring, anti-bioterrorism, and pandemic outbreak

  • Tom Daschle calls for greater U.S.-U.K. bioterror cooperation

    Daschle: “The threat of bioterrorism will increase exponentially because biological agents used to carry out such attacks will continue to become more accessible and more technologically advanced”

  • Investing in biodefense companies

    Billions of dollars are pouring into biodefense vaccines and treatments; do companies engaged in developing such vaccines and treatment offer attractive investment opportunities? The answer is a qualified “Yes” to this specific question — but a more resounding “Yes” when these companies’ other research and development endeavors are taken into consideration

  • India to test anthrax vaccine

    India is worried about bioterror attacks by Islamic extremists; it starts testing the potency of U.S.-manufactured vaccine; initially enough doses will be stored to protect military personnel

  • OSHA issues guidance regarding storage of face masks, respirators

    OSHA requests comments on proposed guidance on workplace stockpiling of respirators and face masks for pandemic influenza

  • Nanotechnology-based biosensor

    NASA develops nanotechnology-based biosensor that can detect trace amounts of specific bacteria, viruses, and parasites; New York-based Early Warning, Inc. will initially market the sensor to water treatment facilities, food and beverage companies, industrial plants, hospitals, and airlines

  • Boston biolab: Panel urges review of possible lab threats

    As community opposition to the almost-complete Boston University biolab continues, a panel of experts says neighborhood’s concerns — and safety — should not be excluded from consideration of final approval for lab opening

  • CDC biolab not ready after 2 1/2 years

    A new CDC biosafety lab was supposed to open in the fall of 2005; it is still not open, and legislators begin to wonder why; they note that at the University of Texas Medical Branch in Galveston, it took less than seven months for its BSL-4 lab to become operational after construction was finished

  • Is the threat of bioterrorism exaggerated?

    William Clark, professor and chair emeritus of immunology at UCLA, says it is

  • A dead end for free trade? I

    Tightening border security along the U.S.-Canada border is hampering trade, experts say; delays owing to security checks have cascading effects, as supplies and raw materials are late arriving at manufacturing plants

  • Market for molecular diagnostic technologies to grow

    The last few years have seen major strides forward in molecular diagnostic technologies; new report asses size of markets and opportunities in it